OBSERVE MEDICAL ASA: Mandatory notification of trade - grant of share options to primary insider

Oslo, 9 April 2026

Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) has today granted 250,000 share options to primary insider and CEO of the Company, Jørgen Mann.

Each share option gives the right to subscribe for or purchase one share in the Company or to receive a cash payment of a NOK amount for each exercised option equal to the market price of the Company's shares less the exercise price. The Company's board of directors shall, at its sole discretion, decide whether options that have been duly exercised shall be settled by either new shares, treasury shares or cash payment.

Shares acquired through exercise of options will be subject to a lock-up period of 12 months, subject to customary exceptions. The share options will vest in full if and when the Company has documented that it has achieved a "cash positive" position during the financial year 2026 (the "Vesting Condition"). Whether the Vesting Condition has been satisfied shall be determined by the board of directors of the Company, in accordance with pre-agreed mechanics and criteria. The share options will be exercisable during specific exercise periods from the date on which the Vesting Condition has been satisfied and will expire and lapse July 22, 2028.

The share options may be exercised at an exercise price equal to the volume -weighted average price of the Company's shares on Euronext Expand over the 10 consecutive trading days commencing on 26 March 2026. Following the grant, Jørgen Mann holds 870,000 shares and 2,116,666 options in the Company. Shares acquired through exercise of options will be subject to a lock-up period of 12 months, subject to customary exceptions.

For more information about the grant of share options to the primary insider, see the attached form regarding mandatory notifications of trade.

This information is subject to disclosure requirements pursuant to Article 19 of Regulation EU 596/2014 (the EU Market Abuse Regulation) and Section 5 -12 of the Norwegian Securities Trading Act.

For further information, please contact:

Jørgen Mann, CEO Observe Medical

Mobile: +45 408 67 558

E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical

Mobile: +47 958 12 765

E-mail: johan.fagerli@observemedical.com

About Observe Medical:

Observe Medical is a Nordic medtech company that develops, markets and sells innovative medtech products for the global market. The Company is committed to improving patient welfare and patient outcomes, improving clinical data accuracy and promoting positive health economics.